Corbadrine, sold under the brand name Neo-Cobefrine and also known as levonordefrin and α-methylnorepinephrine, is a catecholamine sympathomimetic used as a topical nasal decongestant and vasoconstrictor in dentistry in the United States. It is usually used in a pre-mixed solution with local anesthetics, such as mepivacaine.

The drug acts as a non-selective agonist of the α₁-, α₂-, and β-adrenergic receptors. It is said to have preferential activity at the α₂-adrenergic receptor.

Corbadrine is also a metabolite of the antihypertensive drug methyldopa and plays a role in its pharmacology and effects.

Corbadrine is metabolized primarily by catechol O-methyltransferase (COMT).

Corbadrine, also known as 3,4,β-trihydroxy-α-methylphenethylamine or as 3,4,β-trihydroxyamphetamine, as well as α-methylnorepinephrine or (–)-3,4-dihydroxynorephedrine, is a substituted phenethylamine and amphetamine derivative.

Analogues of corbadrine include α-methyldopamine, dioxifedrine (3,4-dihydroxyephedrine; α-methylepinephrine), dioxethedrin (3,4-dihydroxy-N-ethylnorephedrine; α-methyl-N-ethylnorepinephrine), and hydroxyamphetamine (4-hydroxyamphetamine; α-methyltyramine).

Corbadrine is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known as levonordefrin, which is its USANTooltip United States Adopted Name. Synonyms of corbadrine include α-methylnorepinephrine and (–)-3,4-dihydroxynorephedrine. The drug has been sold under the brand name Neo-Cobefrine.